Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of August 2022
Date Filed: August 31, 2022
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves as a cover document incorporating other reports by reference rather than presenting standalone financial data.
Material Changes
No material changes to financial position or operations are detailed in this specific filing text. The document primarily facilitates the incorporation of the company's Form 20-F and XBRL data into existing registration statements.
Guidance, Outlook, and Risks
Management Commentary: None provided in this text.
Guidance/Outlook: Not applicable in this filing.
Risks/Contingencies: Not detailed in this text.
Unusual Items: The filing notes that it is being incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-251647, 333-249311, 333-231417, 333-250076).
Investor Verification Checklist
- Verify the full financial data in the referenced Form 20-F and XBRL data (Exhibit 99.1) as this filing contains no standalone numbers.
- Confirm the status of the incorporated Registration Statements on Form S-8 and Form F-3.
- Note the company's classification as a "development stage enterprise," implying potential lack of commercial revenue.
- Review the signature authorization by Geoffrey P. Kempler, Chairman, dated August 31, 2022.